CARSGEN-B (02171) announced that the abstracts detailing the results of the IIT study for CT0596, a universal CAR-T cell product targeting BCMA for the treatment of relapsed/refractory multiple myeloma/plasma cell leukemia (R/R MM, PCL), and for CT1190B, a universal CAR-T cell product targeting CD19/CD20 for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL), have been accepted for poster presentation at the 2026 European Hematology Association (EHA) Annual Meeting. The abstracts and further information will be released after 15:30 Central European Summer Time on May 12, 2026.

CT0596 is a universal CAR-T cell therapy targeting BCMA, developed using CARSGEN's proprietary THANK-u Plus™ platform. It is currently being evaluated in an IIT for R/R MM or PCL. CT0596 has demonstrated a preliminary favorable safety profile and encouraging efficacy signals. The company also plans to further explore its application in other plasma cell neoplasms and autoimmune diseases driven by autoreactive plasma cells. The company plans to initiate a Phase Ib clinical trial for R/R MM and primary plasma cell lymphoma in 2026.

CT1190B is a universal CAR-T cell therapy targeting CD19/CD20, also developed on the THANK-u Plus™ platform. Ongoing clinical trials for CT1190B include an IIT for treating R/R B-NHL and an IIT for treating moderate-to-severe refractory systemic lupus erythematosus (SLE) or refractory/progressive systemic sclerosis (SSc). The company plans to commence a Phase Ib registration clinical trial for treating R/R B-NHL with this candidate in 2026.